Email Alert RSS
Volume 12 Issue 4
Jul.  2021
Turn off MathJax
Article Contents
Article Navigation >  Medical Journal of Peking Union Medical College Hospital  > 2021  >  12(4): 568-574
HAN Jie, YU Hong. Progress in Immune Markers and Relevant Drug Therapies of Mycosis Fungoides[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 568-574. doi: 10.12290/xhyxzz.20200278
Citation: HAN Jie, YU Hong. Progress in Immune Markers and Relevant Drug Therapies of Mycosis Fungoides[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 568-574. doi: 10.12290/xhyxzz.20200278
shu

Progress in Immune Markers and Relevant Drug Therapies of Mycosis Fungoides

doi: 10.12290/xhyxzz.20200278

  • Department of Dermatology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China

More Information
  • Corresponding author: YU Hong  Tel: 86-21-25076929, E-mail: smallgrass6@163.com
  • Received Date: 2020-11-24
  • Accepted Date: 2021-04-08
    • Available Online: 2021-06-28
  • Publish Date: 2021-07-30
    Abstract
  • Mycosis fungoides (MF) is a primary cutaneous T-cell lymphoma. The pathogenesis is closely associated with immunological abnormalities. Some novel drugs have emerged recently, especially molecular targeted drugs, which are related to the immune markers of MF. Here we summarized the progress of its immune markers and related drug therapies.
    • FullText(HTML)
  • loading
    • References(52)
  • [1] 贾近博, 张乔安, 陈明华. 趋化因子受体4与Foxp3+调节性T细胞在蕈样肉芽肿皮损中的表达及其意义初探[J]. 临床皮肤科杂志, 2014, 43: 389-392. https://www.cnki.com.cn/Article/CJFDTOTAL-LCPF201407002.htm

    Jia JB, Zhang QA, Chen MH. The expression and significance of CC chemokine receptor 4 and Foxp3+ regulatory T cells in mycosis fungoides[J]. Linchuang Pifuke Zazhi, 2014, 43: 389-392. https://www.cnki.com.cn/Article/CJFDTOTAL-LCPF201407002.htm
    [2] Hsi AC, Lee SJ, Rosman IS, et al. Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: diagnostic implications[J]. J Am Acad Dermatol, 2015, 72: 159-167. doi:  10.1016/j.jaad.2014.09.022
    [3] Hodak E, Amitay-Laish I. Mycosis fungoides: A great imitator[J]. Clin Dermatol, 2019, 37: 255-267. doi:  10.1016/j.clindermatol.2019.01.004
    [4] Kalay Yildizhan I, Sanli H, Akay BN, et al. CD8+cytotoxic mycosis fungoides: a retrospective analysis of clinical features and follow-up results of 29 patients[J]. Int J Dermatol, 2020, 59: 127-133. doi:  10.1111/ijd.14689
    [5] Martinez-Escala ME, Kantor RW, Cices A, et al. CD8+ mycosis fungoides: A low-grade lymphoproliferative disorder[J]. J Am Acad Dermatol, 2017, 77: 489-496. doi:  10.1016/j.jaad.2017.05.015
    [6] Kampa F, Mitteldorf C. A review of CD30 expression in cutaneous neoplasms[J]. J Cutan Pathol, 2021, 48: 495-510. doi:  10.1111/cup.13894
    [7] Danish HH, Liu S, Jhaveri J, et al. Validation of cutane-ous lymphoma international prognostic index(CLIPI) for mycosis fungoides and Sézary syndrome[J]. Leuk Lymphoma, 2016, 57: 2813-2819. doi:  10.3109/10428194.2016.1173210
    [8] Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1, 263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009[J]. Clin Cancer Res, 2012, 18: 5051-5060. doi:  10.1158/1078-0432.CCR-12-0604
    [9] Sugaya M, Morimura S, Suga H, et al. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis[J]. J Dermatol, 2015, 42: 613-615. doi:  10.1111/1346-8138.12852
    [10] Shono Y, Suga H, Kamijo H, et al. Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome[J]. Acta Derm Venereol, 2019, 99: 809-812. doi:  10.2340/00015555-3207
    [11] Maj J, Jankowska-Konsur AM, Hałoń A, et al. Expression of CXCR4 and CXCL12 and their correlations to the cell proliferation and angiogenesis in mycosis fungoides[J]. Postepy Dermatol Alergol, 2015, 32: 437-442. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4697019/
    [12] Kakinuma T, Sugaya M, Nakamura K, et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides[J]. J Am Acad Dermatol, 2003, 48: 23-30. doi:  10.1067/mjd.2003.132
    [13] Rubio Gonzalez B, Zain J, Rosen ST, et al. Tumor microenvironment in mycosis fungoides and Sézary syndrome[J]. Curr Opin Oncol, 2016, 28: 88-96. doi:  10.1097/CCO.0000000000000243
    [14] Li X, Sun S, Li N, et al. High Expression of CCR7 Predicts Lymph Node Metastasis and Good Prognosis in Triple Negative Breast Cancer[J]. Cell Physiol Biochem, 2017, 43: 531-539. doi:  10.1159/000480526
    [15] Hu SC, Lin CL, Hong CH, et al. CCR7 expression correlates with subcutaneous involvement in mycosis fungoides skin lesions and promotes migration of mycosis fungoides cells (MyLa) through mTOR activation[J]. J Dermatol Sci, 2014, 74: 31-38. doi:  10.1016/j.jdermsci.2013.12.003
    [16] Hong CH, Lin SH, Lee CH. CCL21 Induces mTOR-dependent MALAT1 Expression, Leading to Cell Migration in Cutaneous T-Cell Lymphoma[J]. In Vivo, 2019, 33: 793-800. doi:  10.21873/invivo.11541
    [17] Pileri A, Agostinelli C, Sessa M, et al. Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease[J]. Virchows Arch, 2017, 470: 575-582. doi:  10.1007/s00428-017-2107-1
    [18] Fawzy MM, El-Latif MIA, Hegazy RA, et al. Expression of langerhans cells, dermal dendritic cells and plasmacytoid dendritic cells in early stage mycosis fungoides: Case control study[J]. J Dermatol Sci, 2016, 84: e24.
    [19] Vieyra-Garcia P, Crouch JD, O'Malley JT, et al. Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma[J]. JCI Insight, 2019, 4: e124233. doi:  10.1172/jci.insight.124233
    [20] Ohmatsu H, Humme D, Gonzalez J, et al. IL-32 induces indoleamine 2, 3-dioxygenase+CD1c+ dendritic cells and indoleamine 2, 3-dioxygenase+CD163+ macrophages: Relevance to mycosis fungoides progression[J]. Oncoimmunology, 2016, 6: e1181237. http://europepmc.org/abstract/MED/28344860
    [21] Ohmatsu H, Humme D, Gulati N, et al. IL32 is progressively expressed in mycosis fungoides independent of helper T-cell 2 and helper T-cell 9 polarization[J]. Cancer Immunol Res, 2014, 2: 890-900. doi:  10.1158/2326-6066.CIR-13-0199-T
    [22] Kado JA, Shango M, Mehregan C, et al. Mapping Toll-like receptor activity in different stages of cutaneous T-cell lymphoma[J]. Am J Dermatopathol, 2012, 34: 691-698. doi:  10.1097/DAD.0b013e3182448f7c
    [23] El Tawdy AM, Amin IM, Abdel Hay RM, et al. Toll-like receptor (TLR)7 expression in mycosis fungoides and psoriasis: a case-control study[J]. Clin Exp Dermatol, 2017, 42: 172-177. doi:  10.1111/ced.13008
    [24] Nguyen GH, Olson LC, Magro CM. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sézary's syndrome[J]. Ann Diagn Pathol, 2017, 28: 54-59. doi:  10.1016/j.anndiagpath.2017.02.003
    [25] Kantekure K, Yang Y, Raghunath P, et al. Expression Patterns of the Immunosuppressive Proteins PD-1/CD279 and PD-L1/CD274 at Different Stages of Cutaneous T-Cell Lymphoma/Mycosis Fungoides[J]. Am J Dermatopathol, 2012, 34: 126-128. doi:  10.1097/DAD.0b013e31821c35cb
    [26] Zic JA. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome[J]. Dermatol Clin, 2015, 33: 765-776. doi:  10.1016/j.det.2015.05.011
    [27] Janiga J, Kentley J, Nabhan C, et al. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome[J]. Leuk Lymphoma, 2018, 59: 562-577. doi:  10.1080/10428194.2017.1347650
    [28] Stewart JR, Desai N, Rizvi S, et al. Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review[J]. Eur J Dermatol, 2018, 28: 764-774. http://www.ncbi.nlm.nih.gov/pubmed/30591425
    [29] Kim YH, Tavallaee M, Sundram U, et al. Phase Ⅱ Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project[J]. J Clin Oncol, 2015, 33: 3750-3758. doi:  10.1200/JCO.2014.60.3969
    [30] Duvic M, Tetzlaff MT, Gangar P, et al. Results of a Phase II Trial of Brentuximab Vedotin for CD30+Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis[J]. J Clin Oncol, 2015, 33: 3759-3765. doi:  10.1200/JCO.2014.60.3787
    [31] Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial[J]. Lancet, 2017, 390: 555-566. doi:  10.1016/S0140-6736(17)31266-7
    [32] Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma[J]. Blood, 2015, 125: 1883-1889. doi:  10.1182/blood-2014-09-600924
    [33] Kasamon YL, Chen H, De Claro RA, et al. FDA Approval Summary: Mogamulizumab-kpkc for Mycosis Fungoides and Sézary Syndrome[J]. Clin Cancer Res, 2019, 25: 7275-7280. doi:  10.1158/1078-0432.CCR-19-2030
    [34] Duvic M, Sherman ML, Wood GS, et al. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides[J]. J Am Acad Dermatol, 2006, 55: 807-813. doi:  10.1016/j.jaad.2006.06.038
    [35] Duvic M, Geskin L, Prince HM. Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies[J]. Clin Lymphoma Myeloma Leuk, 2013, 13: 377-384. doi:  10.1016/j.clml.2013.02.020
    [36] Ohmachi K, Ando K, Ogura M, et al. E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase I study[J]. Cancer Sci, 2018, 109: 794-802. doi:  10.1111/cas.13513
    [37] Kawai H, Ando K, Maruyama D, et al. Phase II study of E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma[J]. Cancer Sci, 2021, 112: 2426-2435. doi:  10.1111/cas.14906
    [38] Ramelyte E, Dummer R, Guenova E. Investigative drugs for the treatment of cutaneous T-cell lymphomas (CTCL): an update[J]. Expert Opin Investig Drugs, 2019, 28: 799-809. doi:  10.1080/13543784.2019.1654995
    [39] Shalabi D, Bistline A, Alpdogan O, et al. Immune evasion and current immunotherapy strategies in mycosis fungoides (MF) and Sézary syndrome (SS)[J]. Chin Clin Oncol, 2019, 8: 11. doi:  10.21037/cco.2019.01.01
    [40] Lewis DJ, Byekova YA, Emge DA, et al. Complete resolution of mycosis fungoides tumors with imiquimod 5% cream: a case series[J]. J Dermatolog Treat, 2017, 28: 567-569. doi:  10.1080/09546634.2017.1294728
    [41] Rook AH, Gelfand JM, Wysocka M, et al. Topical resiquimod can induce disease regression and enhance T-cell effector functions in cutaneous T-cell lymphoma[J]. Blood, 2015, 126: 1452-1461. http://smartsearch.nstl.gov.cn/paper_detail.html?id=2cefd2fbefc79ce641c0b56665910788
    [42] Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study[J]. J Clin Oncol, 2016, 34: 2698-2704. doi:  10.1200/JCO.2015.65.9789
    [43] Khodadoust MS, Rook AH, Porcu P, et al. Pembrolizu-mab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase Ⅱ Study[J]. J Clin Oncol, 2020, 38: 20-28. http://www.researchgate.net/publication/335905923_Pembrolizumab_in_Relapsed_and_Refractory_Mycosis_Fungoides_and_Sezary_Syndrome_A_Multicenter_Phase_II_Study
    [44] Trager MH, Geskin LJ. Current status of histone deacety-lase inhibitors in cutaneous T-cell lymphoma[J]. G Ital Dermatol Venereol, 2019, 154: 681-95. http://www.ncbi.nlm.nih.gov/pubmed/31859467
    [45] Foss F, Advani R, Duvic M, et al. A Phase Ⅱ trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma[J]. Br J Haematol, 2015, 168: 811-819. doi:  10.1111/bjh.13222
    [46] Duvic M, Dummer R, Becker JC, et al. Panobinostat activity in both bexarotene-exposed and -naive patients with refractory cutaneous T-cell lymphoma: results of a phase Ⅱ trial[J]. Eur J Cancer, 2013, 49: 386-394. doi:  10.1016/j.ejca.2012.08.017
    [47] Child F, Ortiz-Romero PL, Alvarez R, et al. Phase Ⅱ multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome[J]. Br J Dermatol, 2016, 175: 80-88. doi:  10.1111/bjd.14427
    [48] Che Y, Ding X, Song J, et al. Effective remission of chidamide on treatment of advanced mycosis fungoides: An unusual case report[J]. Dermatol Ther, 2019, 32: e12944. http://www.ncbi.nlm.nih.gov/pubmed/31012254
    [49] Oka S, Yokote T, Hara S, et al. Effective treatment of a case of refractory mycosis fungoides with imatinib[J]. Br J Haematol, 2006, 133: 353. doi:  10.1111/j.1365-2141.2006.06046.x
    [50] Geskin LJ, Viragova S, Stolz DB, et al. Interleukin-13 is overexpressed in cutaneous T-cell lymphoma cells and regulates their proliferation[J]. Blood, 2015, 125: 2798-2805. doi:  10.1182/blood-2014-07-590398
    [51] Miyashiro D, Vivarelli AG, Gonçalves F, et al. Progres-sion of mycosis fungoides after treatment with dupilumab: A case report[J]. Dermatol Ther, 2020, 33: e13880. doi:  10.1111/dth.13880
    [52] Ayasse M, Nelson K, Glass F, et al. Mycosis Fungoides Unmasked by Dupilumab Treatment in a Patient With a History of Atopic Dermatitis[J]. Dermatitis, 2020. doi: 10.1097/DER.0000000000000679.[Epubaheadofprint].
    • Relative Articles(0)
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (649) PDF downloads(104) Cited by()
    Proportional views
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return